Takeda Pharmaceutical is entering a new phase of growth under President and CEO Julie Kim, with faster drug development, advanced technology and a broader pipeline positioned at the centre of its pharmaceutical strategy.

Kim officially took over as Takeda’s president and CEO on 24 June 2026, following an 18-month transition from former CEO Christophe Weber. She joined Takeda in 2019 through its acquisition of Shire, the Irish-headquartered pharmaceutical company, before leading Takeda’s Plasma-Derived Therapies and U.S. businesses. The Asahi Shimbun reported that Kim is now focused on accelerating upstream drug development and increasing the number of potential medicines in Takeda’s pipeline.

The Shire connection provides an important Irish dimension to Takeda’s next chapter. The 2019 acquisition expanded Takeda’s global portfolio and strengthened its presence across rare diseases, plasma-derived therapies and other specialist medicines. Kim’s experience following the acquisition also gives her a direct connection to the international pharmaceutical organisation that became part of Takeda.

Kim’s immediate focus is on increasing the number and pace of potential medicines moving through development. Takeda has identified three major launches around its current growth cycle, oveporexton, rusfertide and zasocitinib, while continuing to advance additional late-stage assets. Takeda’s 2026 shareholder letter describes the launches and late-stage pipeline as central to the company’s next phase of growth.

Technology is another part of the strategy. Kim has identified advanced technologies, including artificial intelligence, as tools for transforming how Takeda operates, supporting greater efficiency while the company progresses its pipeline. Takeda says its current strategy combines multiple potential launches with continued investment in advanced technologies and organisational transformation.

The approach gives Takeda a clear platform for future pharmaceutical growth. Its existing portfolio provides an established commercial base, while new medicines and late-stage programmes create opportunities to broaden that portfolio and address additional areas of unmet patient need.

For Ireland’s pharmaceutical sector, Takeda’s direction reinforces the continuing international significance of the Shire legacy. The acquisition connected a major Irish-headquartered pharmaceutical business with one of Japan’s largest drugmakers, creating a global platform that continues to influence Takeda’s leadership, portfolio and international operations.

For the sector, Takeda’s transition illustrates how major pharmaceutical companies are combining established portfolios with new medicines, technology and deeper pipelines to support the next generation of growth. For Ireland, the company’s Shire heritage provides a lasting link between the country’s life sciences ecosystem and Takeda’s global pharmaceutical strategy.

Source: The Asahi Shimbun / Takeda Pharmaceutical Co.